Introduction
Sodium bicarbonate injection, with the NDC number 00409-6625, is a critical medication used in various medical settings, including critical care and emergency medicine. This article will delve into the current market situation, pricing dynamics, and future projections for this essential drug.
Current Market Situation
Drug Shortages
Sodium bicarbonate injection has been experiencing shortages, which significantly impact its availability and pricing. As of the latest updates, Pfizer, one of the primary manufacturers, has reported manufacturing delays leading to a shortage of several presentations, including the 8.4% 50 mL vial (NDC 00409-6625-14)[4].
Manufacturer Landscape
Multiple manufacturers are involved in producing sodium bicarbonate injection, including Pfizer, Amphastar, Exela Pharma Sciences, and Fresenius Kabi. However, the current shortage is primarily attributed to Pfizer's manufacturing delays and Fresenius Kabi's inability to estimate a release date for their 4.2% 5 mL vials[4].
Pricing Dynamics
Average Sales Price (ASP)
The pricing of drugs, including sodium bicarbonate injection, is influenced by the Average Sales Price (ASP) reported by manufacturers. The Centers for Medicare and Medicaid Services (CMS) publishes ASP pricing files quarterly, which help in determining the reimbursement rates for Medicare Part B drugs. However, the ASP does not directly dictate the market price, especially during shortages when demand can drive up costs[2].
Market Projections
The Vizient Pharmacy Market Outlook provides insights into pharmaceutical pricing trends. While the overall drug price inflation rate is projected to be 0.00% for 2025, specific drugs like sodium bicarbonate, which are in short supply, may see price fluctuations due to market demand and supply chain disruptions[3].
Impact of Shortages on Pricing
Supply and Demand
During shortages, the demand for available products increases, which can lead to higher prices. For instance, the shortage of Pfizer's 8.4% sodium bicarbonate 50 mL vials (NDC 00409-6625-14) may result in higher prices until the supply is restored, estimated to be around May 2025[4].
Alternative Products
The availability of alternative products from other manufacturers can mitigate price increases to some extent. For example, Amphastar and Exela Pharma Sciences continue to have sodium bicarbonate injection available, which can help stabilize prices[4].
Price Projections for 2025
Given the current shortage and estimated resupply dates, here are some price projection considerations:
Short-Term Projections
- Increased Prices: Until the supply is fully restored, prices for sodium bicarbonate injection, particularly the 8.4% 50 mL vial, are likely to remain elevated due to high demand and limited supply.
- Stabilization: As other manufacturers like Long Grove Pharmaceuticals continue to enter the market, prices may stabilize or decrease slightly as competition increases[4].
Long-Term Projections
- Normalization: By mid-2025, once Pfizer's manufacturing issues are resolved and the supply chain is replenished, prices are expected to normalize to pre-shortage levels.
- Market Stability: The entry of new manufacturers and the resolution of current shortages should lead to a more stable market with competitive pricing by the end of 2025[4].
Implications for Patient Care and Healthcare Providers
Conservation Strategies
During the shortage, healthcare providers are advised to conserve sodium bicarbonate for critical uses, such as advanced cardiac life support (ACLS) and managing metabolic acidosis. This includes drawing up doses from vials to avoid wasting unused product and reviewing storage locations to reduce inventory[4].
Financial Impact
The financial impact of the shortage and subsequent price fluctuations can be significant for healthcare providers. Budgeting and procurement strategies need to be adjusted to account for potential price increases and supply chain disruptions.
Key Takeaways
- Current Shortage: Sodium bicarbonate injection, particularly the 8.4% 50 mL vial (NDC 00409-6625-14), is experiencing a shortage due to Pfizer's manufacturing delays.
- Price Fluctuations: Prices are likely to be elevated until the supply is fully restored, expected around May 2025.
- Alternative Products: Availability of alternative products from other manufacturers can help stabilize prices.
- Long-Term Stability: The market is expected to stabilize by the end of 2025 as new manufacturers enter and supply chains are replenished.
FAQs
What is the current status of the sodium bicarbonate injection shortage?
The sodium bicarbonate injection, particularly the 8.4% 50 mL vial (NDC 00409-6625-14), is currently on back order due to Pfizer's manufacturing delays, with an estimated resupply date of May 2025[4].
How does the shortage affect pricing?
The shortage is likely to drive up prices due to high demand and limited supply. Prices may stabilize or decrease as other manufacturers increase their supply and competition in the market[4].
What are the implications for patient care during the shortage?
Healthcare providers are advised to conserve sodium bicarbonate for critical uses, avoid non-essential uses, and implement strategies to reduce waste and optimize inventory[4].
Which other manufacturers are producing sodium bicarbonate injection?
Other manufacturers include Amphastar, Exela Pharma Sciences, Fresenius Kabi, and Long Grove Pharmaceuticals, which can help mitigate the shortage and stabilize prices[4].
What are the projected price trends for 2025?
Prices are expected to be elevated in the short term but should normalize by mid-2025 as the supply chain is replenished and new manufacturers enter the market[4].
Sources
- ASHP - Drug Shortage Detail: Sodium Bicarbonate Injection
- CMS - ASP Pricing Files
- Vizient Inc. - Pharmacy Market Outlook Summer 2024
- ASHP - Drug Shortage Detail: Sodium Bicarbonate Injection (Updated)
- Merit Pharmaceutical - Sodium Bicarbonate, 8.4%, 1 mEq / mL 50 mL Single Dose Vial
